$274.76
0.35% yesterday
Nasdaq, Dec 24, 08:25 pm CET
ISIN
US74006W1080
Symbol
PRAX

Praxis Precision Medicines Inc Stock price

$274.76
+83.91 43.96% 1M
+230.80 525.02% 6M
+197.80 257.02% YTD
+197.51 255.68% 1Y
+238.46 656.91% 3Y
-515.29 65.22% 5Y
-10.24 3.59% 10Y
-10.24 3.59% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.97 0.35%
ISIN
US74006W1080
Symbol
PRAX
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.6b
Net debt
positive
Cash
$267.2m
Shares outstanding
21.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
924.3 | 22,533.4
EV/Sales
888.5 | 21,660.4
EV/FCF
negative
P/B
20.1
Financial Health
Equity Ratio
92.2%
Return on Equity
-41.0%
ROCE
-85.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $306.0k
EBITDA
$-293.0m | $-303.4m
EBIT
$-293.1m | $-313.8m
Net Income
$-273.0m | $-281.7m
Free Cash Flow
$-228.9m
Growth (TTM | estimate)
Revenue
363.4% | -96.4%
EBITDA
-79.1% | -51.9%
EBIT
-78.7% | -56.8%
Net Income
-80.8% | -54.1%
Free Cash Flow
-130.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,925.4% | -99,165.3%
EBIT
-3,927.5%
Net
-3,658.5% | -92,060.8%
Free Cash Flow
-3,067.4%
More
EPS
$-12.4
FCF per Share
$-10.8
Short interest
14.2%
Employees
116
Rev per Employee
$70.0k
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Praxis Precision Medicines Inc forecast:

19x Buy
90%
1x Hold
5%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
90%
Hold
5%
Sell
5%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7.46 7.46
363% 363%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 55 55
7% 7%
733%
- Research and Development Expense 246 246
115% 115%
3,296%
-293 -293
79% 79%
-3,927%
- Depreciation and Amortization 0.16 0.16
62% 62%
2%
EBIT (Operating Income) EBIT -293 -293
79% 79%
-3,929%
Net Profit -273 -273
81% 81%
-3,660%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
14 days ago
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA
Neutral
GlobeNewsWire
15 days ago
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen
Positive
Investors Business Daily
19 days ago
Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong effectiveness.
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 116
Founded 2015
Website praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today